Evidence map›Paper›PMID 25109438›Full record

ArticleBiomaterials2014

Proliferation and enrichment of CD133(+) glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds.

Forrest M Kievit, Stephen J Florczyk, Matthew C Leung, Kui Wang, Jennifer D Wu, John R Silber, Richard G Ellenbogen, Jerry S H Lee, Miqin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 122 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Biomaterial-basedCancer pathogenesis and therapy · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Forrest M KievitDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, USA.
Stephen J FlorczykDepartment of Materials Science & Engineering, University of Washington, Seattle, WA 98195, USA.
Matthew C LeungDepartment of Materials Science & Engineering, University of Washington, Seattle, WA 98195, USA.
Kui WangDepartment of Materials Science & Engineering, University of Washington, Seattle, WA 98195, USA.
Jennifer D WuDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA; Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
John R SilberDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, USA.
Richard G EllenbogenDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, USA; Department of Radiology, University of Washington, Seattle, WA 98195, USA.
Jerry S H LeeDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA; Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Miqin ZhangDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, USA; Department of Materials Science & Engineering, University of Washington, Seattle, WA 98195, USA. Electronic address: mzhang@u.washington.edu.
University of Washington · USNeurological Surgery · USNational Cancer Institute · US

Funding

Targeting MIC shedding to revive host NKG2D-mediated immune response in prostateR01CA149405 · NCI · UNIVERSITY OF WASHINGTON · PI WU, JENNIFER D · 2010 to 2014
$1.5M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
New 3D tumor models to rapidly test drugs for brain cancer therapyR01CA172455 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2013 to 2016
$1.1M
NCI NIH HHS R01 CA149405NCI NIH HHS R01 CA172455NCI NIH HHS R01CA172455NCI NIH HHS T32 CA138312NCI NIH HHS T32CA138312
6 · The paper itself

Abstract

Emerging evidence implicates cancer stem cells (CSCs) as primary determinants of the clinical behavior of human cancers, representing an ideal target for next-generation anti-cancer therapies. However CSCs are difficult to propagate in vitro, severely limiting the study of CSC biology and drug development. Here we report that growing cells from glioblastoma (GBM) cell lines on three dimensional (3D) porous chitosan-alginate (CA) scaffolds dramatically promotes the proliferation and enrichment of cells possessing the hallmarks of CSCs. CA scaffold-grown cells were found more tumorigenic in nude mouse xenografts than cells grown from monolayers. Growing in CA scaffolds rapidly promoted expression of genes involved in the epithelial-to-mesenchymal transition that has been implicated in the genesis of CSCs. Our results indicate that CA scaffolds have utility as a simple and inexpensive means to cultivate CSCs in vitro in support of studies to understand CSC biology and develop more effective anti-cancer therapies.

Indexed as

AlginatesAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationChitosanEpithelial-Mesenchymal TransitionGlioblastomaGlucuronic AcidHexuronic AcidsHumansMiceMice, NudeMicroscopy, Electron, ScanningNeoplastic Stem CellsTissue ScaffoldsAlginatesAntineoplastic AgentsChitosanGlucuronic AcidHexuronic AcidsBrain tumor initiating cellsEpithelial-to-mesenchymal transitionHyaluronic acidMicroenvironment

Identifiers

PMID25109438
PMCPMC4167581
OpenAlexW1964633780

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.